0000950170-24-077479.txt : 20240625
0000950170-24-077479.hdr.sgml : 20240625
20240625181343
ACCESSION NUMBER: 0000950170-24-077479
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240621
FILED AS OF DATE: 20240625
DATE AS OF CHANGE: 20240625
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hughes-Wilson Alexandra
CENTRAL INDEX KEY: 0002005875
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38452
FILM NUMBER: 241070162
MAIL ADDRESS:
STREET 1: C/O MEREO BIOPHARMA
STREET 2: 1 CAVENDISH PLACE
CITY: LONDON
STATE: X0
ZIP: W1G 0QF
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Mereo BioPharma Group plc
CENTRAL INDEX KEY: 0001719714
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: X0
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE CAVENDISH PLACE
STREET 2: FOURTH FLOOR
CITY: LONDON
STATE: X0
ZIP: W1G0QF
BUSINESS PHONE: 4403330237300
MAIL ADDRESS:
STREET 1: ONE CAVENDISH PLACE
STREET 2: FOURTH FLOOR
CITY: LONDON
STATE: X0
ZIP: W1G0QF
FORMER COMPANY:
FORMER CONFORMED NAME: Mereo Biopharma Group plc
DATE OF NAME CHANGE: 20171016
4
1
ownership.xml
4
X0508
4
2024-06-21
0001719714
Mereo BioPharma Group plc
MREO
0002005875
Hughes-Wilson Alexandra
C/O MEREO BIOPHARMA GROUP PLC
4TH FLOOR, ONE CAVENDISH PLACE
LONDON
X0
W1G 0QF
UNITED KINGDOM
false
true
false
false
See Remarks
false
American Depositary Shares representing Ordinary Shares
2024-06-21
4
M
false
60000
0
A
67650
D
Performance Based Restricted Stock Unit
0
2024-06-21
4
M
false
60000
0
A
2024-06-21
2025-01-25
American Depository Shares
60000
40000
D
Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.
Represents performance-based restricted stock unit ("PSU") earned under the issuer's 2019 Employee Incentive Plan (the "Plan") that vested on June 21, 2024 based on satisfaction of ADS price threshold values over a two year performance period (expiring on January 1, 2025).
Chief Patient Access and Commercial Planning
/s/ Christine Fox, by power of attorney
2024-06-25